Related Experiment Video

Updated: Aug 10, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
06:37

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair

Published on: February 3, 2017

Cardiac IGF-I manipulation by growth hormone following myocardial infarction

K G Matthews1, G P Devlin, S P Stuart

  • 1Functional Muscle Genomics Group, AgResearch Ruakura, Private Bag 3123, East Street, Hamilton, New Zealand.

Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
|May 6, 2004
PubMed

Insights

Growth hormone (GH) treatment post-myocardial infarction increased IGF-I levels and caused significant cardiomyocyte hypertrophy in sheep. This cardiac growth correlated with local IGF-I expression.

Area of Science:

  • Cardiology
  • Endocrinology
  • Molecular Biology

Background:

  • Growth hormone (GH) influences cardiac structure and function, with excess or deficiency linked to reduced lifespan.
  • The specific role of GH in the context of myocardial infarction (heart attack) remains unclear.

Purpose of the Study:

  • To investigate the effects of GH treatment on the ischaemic heart in a sheep model of myocardial infarction.

Main Methods:

  • Sheep with induced myocardial infarction received 30 days of GH treatment.
  • Measurements included circulating IGF-I levels, heart weight, cardiomyocyte size, and IGF-I mRNA expression in cardiac tissue.

Main Results:

  • GH treatment significantly elevated circulating IGF-I levels (P<0.01) and heart weight (P<0.01).
  • A significant increase in cardiomyocyte cross-sectional area (P<0.001) and peri-infarct IGF-I mRNA (P<0.05) was observed.
  • Cardiomyocyte hypertrophy was evident post-treatment.

Conclusions:

  • Post-infarct GH administration boosts circulating and cardiac IGF-I levels, promoting cardiomyocyte hypertrophy.
  • The observed increase in cardiomyocyte size correlates more closely with local cardiac IGF-I expression than with plasma IGF-I levels.

More Related Videos

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model09:19

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Published on: September 20, 2020

A Modified Simple Method for Induction of Myocardial Infarction in Mice04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...